774 results on '"Atsukawa, Masanori"'
Search Results
302. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study
- Author
-
Atsukawa, Masanori, primary, Tsubota, Akihito, additional, Shimada, Noritomo, additional, Kondo, Chisa, additional, Itokawa, Norio, additional, Nakagawa, Ai, additional, Hashimoto, Satomi, additional, Fukuda, Takeshi, additional, Matsushita, Yoko, additional, Kidokoro, Hideko, additional, Narahara, Yoshiyuki, additional, Nakatsuka, Katsuhisa, additional, Iwakiri, Katsuhiko, additional, Kawamoto, Chiaki, additional, and Sakamoto, Choitsu, additional
- Published
- 2013
- Full Text
- View/download PDF
303. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b
- Author
-
Tsubota, Akihito, primary, Shimada, Noritomo, additional, Atsukawa, Masanori, additional, Abe, Hiroshi, additional, Kato, Keizo, additional, Ika, Makiko, additional, Matsudaira, Hiroshi, additional, Nagatsuma, Keisuke, additional, Matsuura, Tomokazu, additional, and Aizawa, Yoshio, additional
- Published
- 2013
- Full Text
- View/download PDF
304. α‐Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir‐based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype
- Author
-
Shimada, Noritomo, primary, Tsubota, Akihito, additional, Atsukawa, Masanori, additional, Abe, Hiroshi, additional, Ika, Makiko, additional, Kato, Keizo, additional, Sato, Yoshiyuki, additional, Kondo, Chisa, additional, Sakamoto, Choitsu, additional, Tanaka, Yasuhito, additional, and Aizawa, Yoshio, additional
- Published
- 2013
- Full Text
- View/download PDF
305. Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites
- Author
-
Taki, Yasuhiko, primary, Kanazawa, Hidenori, additional, Narahara, Yoshiyuki, additional, Itokawa, Norio, additional, Kondo, Chisa, additional, Fukuda, Takeshi, additional, Harimto, Hirotomo, additional, Matsushita, Yoko, additional, Kidokoro, Hideko, additional, Katakura, Tamaki, additional, Atsukawa, Masanori, additional, Kimura, Yuu, additional, Nakatsuka, Katsuhisa, additional, and Sakamoto, Choitsu, additional
- Published
- 2013
- Full Text
- View/download PDF
306. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
- Author
-
Itokawa, Norio, Atsukawa, Masanori, Tsubota, Akihito, Okubo, Tomomi, Arai, Taeang, Nakagawa, Ai, Kondo, Chisa, and Iwakiri, Katsuhiko
- Subjects
- *
LIVER cancer , *SORAFENIB , *THERAPEUTIC use of interferons , *TUMOR classification , *DRUG synergism , *ONCOLOGY , *THERAPEUTICS - Abstract
Background: Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and interferon for HCC. To clarify the efficacy, combination therapy with sorafenib and interferon was performed for patients with advanced HCC. Methods: Pegylated interferon α-2a was administered every 2 weeks for the initial 4 weeks. Subsequently, it was combined with sorafenib. We evaluated the anti-tumor effect and biomarkers during treatment period. Results: The subjects were 13 patients with advanced HCC complicated by hepatitis C virus (HCV)-related liver cirrhosis. A partial response, stable disease and progressive disease were noted in 4, 6, and 3 patients, respectively. The response rate, the disease control rate, the mean time to progression and the median survival time (MST) were 30.8 % (4/13), 76.9 % (10/13), 12.2 months, and 17.5 months, respectively. In 8 Child-Pugh class A and 5 Child-Pugh class B patients, the MST was 22.0 and 11.0 months, respectively ( p = 0.001). In plasma vascular endothelial growth factor (VEGF), serum alpha-fetoprotein (AFP), AFP-L3, a protein induced by vitamin K absence or antagonist-II (PIVKA II), and hepatocyte growth factor (HGF), there was no pretreatment factor and no biomarker during the combination therapy to predict therapeutic effect in the present study. Conclusions: The results of this study suggest that combination therapy with sorafenib and interferon could be effective and safe in advanced HCC patients with HCV-related liver cirrhosis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
307. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin.
- Author
-
Atsukawa, Masanori, Tsubota, Akihito, Shimada, Noritomo, Yoshizawa, Kai, Abe, Hiroshi, Asano, Toru, Ohkubo, Yusuke, Araki, Masahiro, Ikegami, Tadashi, Okubo, Tomomi, Kondo, Chisa, Osada, Yuji, Nakatsuka, Katsuhisa, Chuganji, Yoshimichi, Matsuzaki, Yasushi, Iwakiri, Katsuhiko, and Aizawa, Yoshio
- Subjects
- *
VITAMIN D , *HEPATITIS C , *CHRONIC diseases , *INTERFERONS , *RIBAVIRIN ,SULFONAMIDE drugs - Abstract
Aim Protease inhibitors with pegylated interferon (PEG IFN)/ribavirin improve a sustained virological response (SVR) rate to approximately 90% in chronic hepatitis C genotype 1b patients with IL28B rs8099917 genotype TT, but yield only approximately 50% in those with the unfavorable non-TT. Among such treatment-refractory patients, serum vitamin D levels could influence the SVR rate. This randomized controlled trial was conducted to assess the effect of native vitamin D supplementation in simeprevir with PEG IFN/ribavirin for 1b patients with non-TT. Methods Patients were randomly assigned to receive simeprevir (100 mg/day) for 12 weeks plus PEG IFN/ribavirin for 24 weeks (control group, n = 58), or vitamin D (2000 IU/day) for 16 weeks including a lead-in phase plus PEG IFN/ribavirin for 24 weeks (vitamin D group, n = 57). The primary end-point was sustainably undetectable viremia 24 weeks after the end of treatment (SVR). Results SVR rates were 37.9% in the control group and 70.2% in the vitamin D group. In subgroup analysis, SVR rates of prior null responders were 11.8% and 54.5%, respectively. SVR rates for advanced fibrosis were 28.6% and 65.4%. SVR rates for patients with vitamin D3 deficiency at the baseline were 25.0% in the control group and 66.7% in the vitamin D group. Overall, the SVR rate was significantly higher in patients with high serum 25(OH)D3 levels at the beginning of combination therapy than in those with low serum 25(OH)D3 levels. Conclusion Native vitamin D3 supplementation improved SVR rates in simeprevir with PEG IFN/ribavirin for chronic hepatitis C genotype 1b patients with refractory factors. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
308. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b
- Author
-
Atsukawa, Masanori, primary, Tsubota, Akihito, additional, Kondo, Chisa, additional, Itokawa, Norio, additional, Narahara, Yoshiyuki, additional, Nakatsuka, Katsuhisa, additional, Hashimoto, Satomi, additional, Fukuda, Takeshi, additional, Matsushita, Yoko, additional, Kidokoro, Hideko, additional, Kobayashi, Tamaki, additional, Kanazawa, Hidenori, additional, and Sakamoto, Choitsu, additional
- Published
- 2012
- Full Text
- View/download PDF
309. Ribavirin modulates the conversion of human CD4+ CD25−T cell to CD4+ CD25+ FOXP3+T cell via suppressing interleukin-10-producing regulatory T cell
- Author
-
Kobayashi, Tamaki, primary, Nakatsuka, Katsuhisa, additional, Shimizu, Masumi, additional, Tamura, Hideto, additional, Shinya, Eiji, additional, Atsukawa, Masanori, additional, Harimoto, Hirotomo, additional, Takahashi, Hidemi, additional, and Sakamoto, Choitsu, additional
- Published
- 2012
- Full Text
- View/download PDF
310. Effects of transjugular intrahepatic portosystemic shunt on changes in the small bowel mucosa of cirrhotic patients with portal hypertension
- Author
-
Matsushita, Yoko, primary, Narahara, Yoshiyuki, additional, Fujimori, Shunji, additional, Kanazawa, Hidenori, additional, Itokawa, Norio, additional, Fukuda, Takeshi, additional, Takahashi, Yoko, additional, Kondo, Chisa, additional, Kidokoro, Hideko, additional, Atsukawa, Masanori, additional, Nakatsuka, Katsuhisa, additional, and Sakamoto, Choitsu, additional
- Published
- 2012
- Full Text
- View/download PDF
311. Factors contributing to rapid virological response to triple therapy with peginterferon alfa-2b, ribavarin and telaprevir in chronic hepatitis C patients infected with genotype1b: Multicenter trial
- Author
-
Shimada, Noritomo, primary, Atsukawa, Masanori, additional, Tsubota, Akihito, additional, Yoshizawa, Kai, additional, Abe, Hiroshi, additional, Kato, Keizo, additional, Ika, Makiko, additional, Adachi, Satoshi, additional, Tachibana, Hiroyuki, additional, Sato, Yoshiyuki, additional, Toda, Gotaro, additional, Kondo, Chisa, additional, Fukuda, Takeshi, additional, Sakamoto, Choitsu, additional, and Aizawa, Yoshio, additional
- Published
- 2012
- Full Text
- View/download PDF
312. The effects of interferon-beta on portal pressure and serum hepatic fibrotic markers in patients with hepatitis C virus-related cirrhosis: An interim results
- Author
-
Kanazawa, Hidenori, primary, Narahara, Yoshiyuki, additional, Fukuda, Takeshi, additional, Kondoh, Chisa, additional, Harimoto, Hirotomo, additional, Matsushita, Yoko, additional, Kidokoro, Hideko, additional, Katakura, Tamaki, additional, Atsukawa, Masanori, additional, Nakatsuka, Katsuhisa, additional, and Sakamoto, Choitsu, additional
- Published
- 2011
- Full Text
- View/download PDF
313. Two cases of alcoholic liver cirrhosis with diffuse intrahepatic arterio-portal shunt treated by transjugular intrahepatic portosystemic shunt
- Author
-
Fukuda, Takeshi, primary, Narahara, Yoshiyuki, additional, Kanazawa, Hidenori, additional, Itokawa, Norio, additional, Kondo, Chisa, additional, Harimoto, Hirotomo, additional, Matsushita, Yoko, additional, Kidokoro, Hideko, additional, Kobayashi, Tamaki, additional, Atsukawa, Masanori, additional, Nakatsuka, Katsuhisa, additional, and Sakamoto, Choitsu, additional
- Published
- 2011
- Full Text
- View/download PDF
314. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial
- Author
-
Narahara, Yoshiyuki, primary, Kanazawa, Hidenori, additional, Fukuda, Takeshi, additional, Matsushita, Yoko, additional, Harimoto, Hirotomo, additional, Kidokoro, Hideko, additional, Katakura, Tamaki, additional, Atsukawa, Masanori, additional, Taki, Yasuhiko, additional, Kimura, Yuu, additional, Nakatsuka, Katsuhisa, additional, and Sakamoto, Choitsu, additional
- Published
- 2010
- Full Text
- View/download PDF
315. Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients.
- Author
-
Atsukawa, Masanori, Tsubota, Akihito, Shimada, Noritomo, Yoshizawa, Kai, Abe, Hiroshi, Asano, Toru, Ohkubo, Yusuke, Araki, Masahiro, Ikegami, Tadashi, Kondo, Chisa, Itokawa, Norio, Nakagawa, Ai, Arai, Taeang, Matsushita, Yoko, Nakatsuka, Katsuhisa, Furihata, Tomomi, Chuganji, Yoshimichi, Matsuzaki, Yasushi, Aizawa, Yoshio, and Iwakiri, Katsuhiko
- Subjects
- *
SERUM , *VITAMIN D , *HEPATITIS C , *PATIENT acceptance of health care , *DEFICIENCY diseases , *PATIENTS - Abstract
Background: Serum 25-hydroxyvitamin D3 levels are generally lower in chronic hepatitis C patients than in healthy individuals. The purpose of this study is to clarify the factors which affect serum 25-hydroxyvitamin D3 levels using data obtained from Japanese chronic hepatitis C patients. Methods: The subjects were 619 chronic hepatitis C patients. Serum 25-hydroxyvitamin D3 levels were measured by using double-antibody radioimmunoassay between April 2009 and August 2014. Serum 25-hydroxyvitamin D3 levels of 20 ng/mL or less were classified as vitamin D deficiency, and those with serum 25-hydroxyvitamin D3 levels of 30 ng/mL or more as vitamin D sufficiency. The relationship between patient-related factors and serum 25-hydroxyvitamin D3 levels was analyzed. Results: The cohort consisted of 305 females and 314 males, aged between 18 and 89 years (median, 63 years). The median serum 25-hydroxyvitamin D3 level was 21 ng/mL (range, 6-61 ng/mL). On the other hand, the median serum 25-hydroxyvitamin D3 level in the healthy subjects was 25 ng/mL (range, 7-52), being significantly higher than that those in 80 chronic hepatitis C patients matched for age, gender, and season (p = 1.16 × 10-8). In multivariate analysis, independent contributors to serum 25-hydroxyvitamin D3 deficiency were as follows: female gender (p = 2.03 × 10-4, odds ratio = 2.290, 95 % confidence interval = 1.479-3.545), older age (p = 4.30 × 10-4, odds ratio = 1.038, 95 % confidence interval = 1.017-1.060), cold season (p = 0.015, odds ratio = 1.586, 95 % confidence interval = 1.095-2.297), and low hemoglobin level (p = 0.037, odds ratio = 1.165, 95 % confidence interval = 1.009-1.345). By contrast, independent contributors to serum 25-hydroxyvitamin D3 sufficiency were male gender (p = 0.001, odds ratio = 3.400, 95 % confidence interval = 1.635-7.069), warm season (p = 0.014, odds ratio = 1.765, 95 % confidence interval = 1.117-2.789) and serum albumin (p = 0.016, OR = 2.247, 95 % CI = 1.163-4.342). Conclusions: Serum 25-hydroxyvitamin D3 levels in chronic hepatitis C Japanese patients were influenced by gender, age, hemoglobin level, albumin and the season of measurement. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
316. Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load.
- Author
-
Atsukawa, Masanori, Tsubota, Akihito, Shimada, Noritomo, Kondo, Chisa, Itokawa, Norio, Nakagawa, Ai, Hashimoto, Satomi, Fukuda, Takeshi, Matsushita, Yoko, Narahara, Yoshiyuki, Iwakiri, Katsuhiko, Nakatsuka, Katsuhisa, Kawamoto, Chiaki, and Sakamoto, Choitsu
- Subjects
- *
BLOOD serum analysis , *VITAMIN D , *HEALTH outcome assessment , *RIBAVIRIN , *DRUG therapy , *CIRRHOSIS of the liver , *HEPATITIS C virus , *PATIENTS - Abstract
Aim Much is unknown about the effect of 25-hydroxyvitamin D3 levels on the outcome of pegylated interferon/ribavirin ( PEG IFN/ RBV) therapy for hepatitis C virus-related cirrhosis. The purpose of the present study was to analyze and elucidate factors, including 25-hydroxyvitamin D3, that contribute to a sustained virological response ( SVR) in patients with cirrhosis. Methods We analyzed whether 25-hydroxyvitamin D3 contributes to the response to PEG IFN/ RBV therapy among 134 cirrhotic patients. Results SVR was achieved in 43 patients. The median 25-hydroxyvitamin D3 level was 20 ng/mL. Univariate analysis showed that the following factors contributed to SVR: low-density lipoprotein cholesterol, albumin, 25-hydroxyvitamin D3, core a.a.70 (a.a.70) substitutions, the number of mutations at the interferon sensitivity-determining region and IL28B genotype. Multivariate analysis identified IL28B genotype and 25-hydroxyvitamin D3 as independent factors contributing to SVR. Subsequently, SVR rate was examined by using 25-hydroxyvitamin D3 and other important factors. The SVR rate was 51.8% in patients with core a.a.70 wild and ≥15 ng/mL of 25-hydroxyvitamin D3, whereas the SVR rate was 7.1% in patients with core a.a.70 wild and <15 ng/mL of 25-hydroxyvitamin D3. The SVR rate was 56.9% in patients with IL28B major genotype and ≥15 ng/mL of 25-hydroxyvitamin D3. Surprisingly, the SVR rate was 0% in patients with IL28B minor genotype and <15 ng/mL of 25-hydroxyvitamin D3. Conclusion IL28B genotype and 25-hydroxyvitamin D3 were identified as independent factors contributing to SVR. Stratified analyses according to core a.a.70 substitution and IL28B genotype suggested that 25-hydroxyvitamin D3 influences the outcome of PEG IFN/ RBV therapy for cirrhosis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
317. The best predictive model for post-SVR HCC: can it be universal?
- Author
-
Toyoda, Hidenori and Atsukawa, Masanori
- Published
- 2022
- Full Text
- View/download PDF
318. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL 28 B minor genotype.
- Author
-
Shimada, Noritomo, Tsubota, Akihito, Atsukawa, Masanori, Abe, Hiroshi, Ika, Makiko, Kato, Keizo, Sato, Yoshiyuki, Kondo, Chisa, Sakamoto, Choitsu, Tanaka, Yasuhito, and Aizawa, Yoshio
- Abstract
Even when treated with telaprevir-based triple therapy, some patients fail to achieve a sustained virological response. This study identified factors related closely to treatment failure. A total of 146 Japanese genotype 1b chronic hepatitis C patients were enrolled in this prospective, multicenter study and received a 24-week regimen of triple therapy. The end-of-treatment response rate was significantly lower in patients with the interleukin 28B ( IL28B) (rs8099917) non-TT genotype (85.2%) than in those with the TT genotype (100%, P = 0.0002). Multiple logistic regression analysis identified high α-fetoprotein levels as an independent factor related to non-end-of-treatment response in patients with the non-TT genotype. A cut-off value of 20 ng/ml was determined for a non-end-of-treatment response; sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were 75.0%, 95.7%, 75.0%, 75.0%, and 92.6%, respectively. Multiple logistic regression analysis for a sustained virological response identified the IL28B TT genotype, low α-fetoprotein levels, non-responders, and a rapid virological response. The sustained virological response rate was significantly lower in patients with the non-TT genotype (59.3%) than in those with the TT genotype (96.7%, P < 0.0001). In patients with the non-TT genotype, α-fetoprotein was the most significant predictor for non-sustained virological response by univariate analysis. A cut-off value of 7.4 ng/ml α-fetoprotein was determined for non-sustained virological response; sensitivity, specificity, PPV, NPV, and accuracy were 63.6%, 87.5%, 77.8%, 77.8%, and 77.8%, respectively. For the non-TT patients, serum α-fetoprotein levels may be a surrogate marker for predicting treatment failure in telaprevir-based therapy for genotype 1b chronic hepatitis C. J. Med. Virol. 86:461-472, 2014. © 2013 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
319. Ribavirin modulates the conversion of human CD4+ CD25− T cell to CD4+ CD25+ FOXP3+ T cell via suppressing interleukin-10-producing regulatory T cell.
- Author
-
Kobayashi, Tamaki, Nakatsuka, Katsuhisa, Shimizu, Masumi, Tamura, Hideto, Shinya, Eiji, Atsukawa, Masanori, Harimoto, Hirotomo, Takahashi, Hidemi, and Sakamoto, Choitsu
- Subjects
RIBAVIRIN ,GENETIC regulation ,T cells ,INTERLEUKIN-10 ,IMMUNE system ,IMMUNE response ,CANCER immunotherapy ,CELLULAR immunity - Abstract
Because regulatory T ( Treg) cells play an important role in modulating the immune system response against both endogenous and exogenous antigens, their control is critical to establish immunotherapy against autoimmune disorders, chronic viral infections and tumours. Ribavirin ( RBV), an antiviral reagent used with interferon, is known to polarize the T helper ( Th) 1/2 cell balance toward Th1 cells. Although the immunoregulatory mechanisms of RBV are not fully understood, it has been expected that RBV would affect T reg cells to modulate the Th1/2 cell balance. To confirm this hypothesis, we investigated whether RBV modulates the inhibitory activity of human peripheral CD4
+ CD25+ CD127− T cells in vitro. CD4+ CD25+ CD127− T cells pre-incubated with RBV lose their ability to inhibit the proliferation of CD4+ CD25− T cells. Expression of Forkhead box P3 ( FOXP3) in CD4+ CD25− T cells was down-modulated when they were incubated with CD4+ CD25+ CD127− T cells pre-incubated with RBV without down-modulating CD45 RO on their surface. In addition, transwell assays and cytokine-neutralizing assays revealed that this effect depended mainly on the inhibition of interleukin-10 ( IL-10) produced from CD4+ CD25+ CD127− T cells. These results indicated that RBV might inhibit the conversion of CD4+ CD25− FOXP3− naive T cells into CD4+ CD25+ FOXP3+ adaptive Treg cells by down-modulating the IL-10-producing Treg 1 cells to prevent these effector T cells from entering anergy and to maintain Th1 cell activity. Taken together, our findings suggest that RBV would be useful for both elimination of long-term viral infections such as hepatitis C virus infection and for up-regulation of tumour-specific cellular immune responses to prevent carcinogenesis, especially hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
320. Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance.
- Author
-
Atsukawa, Masanori, Nakatsuka, Katsuhisa, Kobayashi, Tamaki, Shimizu, Masumi, Tamura, Hideto, Harimoto, Hirotomo, Takahashi, Hidemi, and Sakamoto, Choitsu
- Subjects
- *
RIBAVIRIN , *T cells , *INTERLEUKIN-10 , *HEPATITIS C virus , *CYTOKINES , *DENDRITIC cells , *HEPATITIS C , *PATIENTS - Abstract
Background and Aim: The immunological mechanism by which ribavirin (RBV) polarizes the T-helper (Th) 1/2 balance toward Th1 predominancy is not fully understood. We therefore examined whether RBV affects costimulatory signaling, which is known to be essential for regulating the Th1/2 balance. Methods: The expression of costimulatory molecules and their ligands, and levels of various cytokines, released from CD4+ T cells obtained from healthy individuals or patients with chronic hepatitis C virus (HCV) infection were analyzed. Results: In CD4+ T cells, RBV selectively downmodulates the expression of inducible costimulator (ICOS), a ligand for B7-H2 on dendritic cells, which mainly differentiates Th0 into Th2 cells. Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4+ T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. An analysis of the association between ICOS kinetics and hepatitis C virus (HCV) elimination in hepatitis C patients receiving combined pegylated interferon and RBV indicated that HCV elimination tended to occur more frequently in patients showing ICOS downmodulation with RBV treatment. A decrease in IL-10 production by CD4+ T cells was also observed in association with ICOS downregulation in patients who succeeded in HCV elimination. Conclusions: The downmodulation of ICOS in correlation with a reduction in IL-10 produced by CD4+ T cells is possibly the immunological mechanism of action of RBV, which polarizes the Th1/2 balance toward a Th1 cytokine profile, thus contributing to the elimination of cells chronically infected with HCV. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
321. THU056 - Risk factors associated with subclinical atherosclerosis in the patients with biopsy-proven non-alcoholic fatty liver disease.
- Author
-
Arai, Taeang, Atsukawa, Masanori, Tsubota, Akihito, Yoshida, Yuji, Okubo, Tomomi, Hayama, Korenobu, Nakagawa, Ai, Itokawa, Norio, Kondo, Chisa, Iio, Etsuko, Tanaka, Yasuhito, and Iwakiri, Katsuhiko
- Subjects
- *
ATHEROSCLEROSIS , *FATTY liver - Published
- 2020
- Full Text
- View/download PDF
322. Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.
- Author
-
Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Toyoda, Hidenori, Ogawa, Chikara, Nishikawa, Hiroki, Nishimura, Takashi, Kawata, Kazuhito, and Kosaka, Hisashi
- Subjects
- *
CONVERSION therapy , *NEUTROPHIL lymphocyte ratio , *OVERALL survival , *HEPATOCELLULAR carcinoma , *SURVIVAL rate , *BEVACIZUMAB - Abstract
Summary Aim Methods Results Conclusions This study aims to investigate the predictive factors for conversion therapy in patients with unresectable hepatocellular carcinoma (uHCC) and to evaluate the prognosis of conversion cases by comparing them with partial response (PR) and complete response (CR) cases.In this retrospective multicentre study, we included a total of 946 uHCC patients treated with atezolizumab and bevacizumab (Atez/Bev) from September 2020 to September 2023.Out of the patients, 43 (4.5%) received conversion therapy following Atez/Bev treatment. The overall response rate was 65.1% and 23.7% in the conversion and non‐conversion group, respectively, with a statistical significance (p < 0.001). Multivariate analyses identified that BCLC stage B or an earlier stage (p = 0.045), absence of macrovascular invasion and extrahepatic spread (p = 0.045), and a low value of neutrophil to lymphocyte ratio (p = 0.04) were significantly favourable predictive factors associated with conversion therapy. The conversion group showed significantly better survival compared to the non‐conversion group (p < 0.001). In the landmark analysis at 6, 12 and 18 months, the conversion group exhibited better survival compared to PR patients in the non‐conversion group (p = 0.04, 0.01 and 0.03, respectively) and there were no significant differences in the overall survival (OS) between the conversion group and patients who achieved a CR (p = 0.7, 1.0 and 0.3, respectively).Patients with low tumour burden and low value of NLR were more likely to undergo conversion therapy. The OS of patients undergoing conversion therapy showed better survival compared to those achieving PR and was comparable to those with CR patients. Conversion therapy could be considered if feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
323. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
- Author
-
Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Nishikawa, Hiroki, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Koshiyama, Yuichi, Toyoda, Hidenori, Ogawa, Chikara, Hatanaka, Takeshi, Kakizaki, Satoru, and Kawata, Kazuhito
- Subjects
- *
CLINICAL trials , *HEPATOCELLULAR carcinoma , *ATEZOLIZUMAB , *BEVACIZUMAB , *OVERALL survival - Abstract
Summary: Background: Atezolizumab plus bevacizumab (Atezo/Bev) is frequently selected as the primary systemic therapy for hepatocellular carcinoma (HCC). Aims: To investigate the outcomes of patients with HCC treated with Atezo/Bev in a real‐world setting based on whether they met the inclusion criteria for the phase 3 IMbrave150 trial. Methods: A total of 936 patients were enrolled. There were 404 patients who met the inclusion criteria of the phase 3 IMbrave150 trial (IMbrave150 group) and 532 who did not (non‐IMbrave150 group). Results: Median progression‐free survival (PFS) in the IMbrave150 and non‐IMbrave150 groups was 7.4 months and 5.6 months (p = 0.002). Multivariable analysis revealed that non‐B, non‐C HCC aetiology (hazard ratio [HR], 1.173), α‐fetoprotein ≥100 ng/mL (HR, 1.472), Barcelona Clinic Liver Cancer stage ≥ C (HR, 1.318), and modified albumin–bilirubin (mALBI) grade 2b or 3 (HR, 1.476) are independently associated with PFS. Median overall survival (OS) in the IMbrave150 and non‐Imbrave150 groups was 26.5 and 18.8 months (p < 0.001). Multivariable analysis revealed that Eastern Cooperative Oncology Group performance status ≥2 (HR, 1.986), α‐fetoprotein ≥100 ng/mL (HR, 1.481), and mALBI grade 2b or 3 (HR, 2.037) are independently associated with OS. In subgroup analysis, there were no significant differences in PFS or OS between these groups among patients with mALBI grade 1 or 2a. Conclusions: Patients who are treated with Atezo/Bev and meet the inclusion criteria for the phase 3 IMbrave150 trial, as well as those who do not meet the inclusion criteria but have good liver function, have a good prognosis for survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
324. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world.
- Author
-
Kudaravalli, Sahith, Huang, Daniel Q., Yeh, Ming-Lun, Trinh, Lindsey, Tsai, P.C., Hsu, Yao-Chun, Kam, Leslie Y., Nguyen, Vy H., Ogawa, Eiichi, Lee, Dong Hyun, Ito, Takanori, Watanabe, Tsunamasa, Enomoto, Masaru, Preda, Carmen Monica, Ko, Michael K.L., Wan-Hin Hui, Rex, Atsukawa, Masanori, Suzuki, Takanori, Marciano, Sebastian, and Barreira, Ana
- Subjects
- *
HEPATITIS B , *CHRONIC hepatitis B , *ASIANS , *LOGISTIC regression analysis , *ASIAN Americans - Abstract
Oral antiviral therapy with nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB) is well-tolerated and lifesaving, but real-world data on utilization are limited. We examined rates of evaluation and treatment in patients from the REAL-B consortium. This was a cross-sectional study nested within our retrospective multinational clinical consortium (2000-2021). We determined the proportions of patients receiving adequate evaluation, meeting AASLD treatment criteria, and initiating treatment at any time during the study period. We also identified factors associated with receiving adequate evaluation and treatment using multivariable logistic regression analyses. We analyzed 12,566 adult treatment-naïve patients with CHB from 25 centers in 9 countries (mean age 47.1 years, 41.7% female, 96.1% Asian, 49.6% Western region, 8.7% cirrhosis). Overall, 73.3% (9,206 patients) received adequate evaluation. Among the adequately evaluated, 32.6% (3,001 patients) were treatment eligible by AASLD criteria, 83.3% (2,500 patients) of whom were initiated on NAs, with consistent findings in analyses using EASL criteria. On multivariable logistic regression adjusting for age, sex, cirrhosis, and ethnicity plus region, female sex was associated with adequate evaluation (adjusted odds ratio [aOR] 1.13, p = 0.004), but female treatment-eligible patients were about 50% less likely to initiate NAs (aOR 0.54, p <0.001). Additionally, the lowest evaluation and treatment rates were among Asian patients from the West, but no difference was observed between non-Asian patients and Asian patients from the East. Asian patients from the West (vs. East) were about 40-50% less likely to undergo adequate evaluation (aOR 0.60) and initiate NAs (aOR 0.54) (both p <0.001). Evaluation and treatment rates were suboptimal for patients with CHB in both the East and West, with significant sex and ethnic disparities. Improved linkage to care with linguistically competent and culturally sensitive approaches is needed. Significant sex and ethnic disparities exist in hepatitis B evaluation and treatment, with female treatment-eligible patients about 50% less likely to receive antiviral treatment and Asian patients from Western regions also about 50% less likely to receive adequate evaluation or treatment compared to Asians from the East (there was no significant difference between Asian patients from the East and non-Asian patients). Improved linkage to care with linguistically competent and culturally sensitive approaches is needed. [Display omitted] • Among 12,566 patients with chronic HBV infection, about one-quarter were not adequately evaluated. • Among adequately evaluated patients, about one-third were treatment eligible by international guidelines. • Among those who were treatment eligible, about 80-85% were treated. • Treatment rates were lower in females and Asian Americans (vs. Asians from the East or non-Asians). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
325. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants.
- Author
-
Yoshida, Kyoko, Desbiolles, Alice, Feldman, Sarah F., Ahn, Sang Hoon, Alidjinou, Enagnon K., Atsukawa, Masanori, Bocket, Laurence, Brunetto, Maurizia R., Buti, Maria, Carey, Ivana, Caviglia, Gian Paolo, Chen, En-Qiang, Cornberg, Markus, Enomoto, Masaru, Honda, Masao, Zu Siederdissen, Christoph Höner, Ishigami, Masatoshi, Janssen, Harry L.A., Maasoumy, Benjamin, and Matsui, Takeshi
- Abstract
To eliminate hepatitis B virus (HBV) infection, scale-up of testing and treatment in resource-limited countries is crucial. However, access to nucleic acid testing to quantify HBV DNA, an essential test to examine treatment eligibility, remains severely limited. We assessed the performance of a novel immunoassay, HBV core-related antigen (HBcrAg), as a low-cost (less than US $15/assay) alternative to nucleic acid testing to indicate clinically important high viremia in chronic HBV patients infected with different genotypes. We searched Medline, Embase, Scopus, and Web of Science databases through June 27, 2018. Three reviewers independently selected studies measuring HBV DNA and HBcrAg in the same blood samples. We contacted authors to provide individual participant data (IPD). We randomly allocated each IPD to a derivation or validation cohort. We applied optimal HBcrAg cut-off values derived from the derivation set to the validation set to estimate sensitivity/specificity. Of 74 eligible studies, IPD were obtained successfully for 60 studies (81%). Meta-analysis included 5591 IPD without antiviral therapy and 4806 treated with antivirals. In untreated patients, the pooled area under the receiver operating characteristic curve and optimal cut-off values were as follows: 0.88 (95% CI, 0.83–0.94) and 3.6 log U/mL to diagnose HBV DNA level of 2000 IU/mL or greater; and 0.96 (95% CI, 0.94–0.98) and 5.3 log U/mL for 200,000 IU/mL or greater, respectively. In the validation set, the sensitivity and specificity were 85.2% and 84.7% to diagnose HBV DNA level of 2000 IU/mL or greater, and 91.8% and 90.5% for 200,000 IU/mL or greater, respectively. The performance did not vary by HBV genotypes. In patients treated with anti-HBV therapy the correlation between HBcrAg and HBV DNA was poor. HBcrAg might be a useful serologic marker to indicate clinically important high viremia in treatment-naïve, HBV-infected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
326. SAT-236 Efficacy and safety of incretin-based therapies in patients with metabolic dysfunction-associated steatotic liver disease complicated by type 2 diabetes mellitus.
- Author
-
Kawano, Tadamichi, Arai, Taeang, Atsukawa, Masanori, Tada, Toshifumi, Oikawa, Tsunekazu, Tsubota, Akihito, Matsuura, Kentaro, Ishikawa, Toru, Abe, Hiroshi, Kato, Keizo, Morishita, Asahiro, Tani, Joji, Okubo, Tomomi, and Iwakiri, Katsuhiko
- Published
- 2024
- Full Text
- View/download PDF
327. Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.
- Author
-
Jang, Tyng‐Yuan, Liang, Po‐Cheng, Jun, Dae Won, Jung, Jang Han, Toyoda, Hidenori, Wang, Chih‐Wen, Yuen, Man‐Fung, Cheung, Ka Shing, Yasuda, Satoshi, Kim, Sung Eun, Yoon, Eileen L, An, Jihyun, Enomoto, Masaru, Kozuka, Ritsuzo, Chuma, Makoto, Nozaki, Akito, Ishikawa, Toru, Watanabe, Tsunamasa, Atsukawa, Masanori, and Arai, Taeang
- Subjects
- *
CHRONIC hepatitis B , *DNA viruses , *PROPENSITY score matching , *HEPATITIS B virus , *TENOFOVIR - Abstract
Background and Aim: The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)‐related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated with ETV and those treated with TDF is unclear. Methods: A total of 2542 patients with CHB treated with either ETV or TDF were recruited from a multinational cohort. A 1:1 propensity score matching was performed to balance the differences in baseline characteristics between the two patient groups. We aimed to compare the all‐cause, liver‐related, and non‐liver‐related mortality between patients receiving ETV and those receiving TDF. Results: The annual incidence of all‐cause mortality in the entire cohort was 1.0/100 person‐years (follow‐up, 15 757.5 person‐years). Patients who received TDF were younger and had a higher body mass index, platelet count, hepatitis B virus deoxyribonucleic acid levels, and proportion of hepatitis B e‐antigen seropositivity than those who received ETV. The factors associated with all‐cause mortality were fibrosis‐4 index > 6.5 (hazard ratio [HR]/confidence interval [CI]: 3.13/2.15–4.54, P < 0.001), age per year increase (HR/CI: 1.05/1.04–1.07, P < 0.001), alanine aminotransferase level per U/L increase (HR/CI: 0.997/0.996–0.999, P = 0.003), and γ‐glutamyl transferase level per U/L increase (HR/CI: 1.002/1.001–1.003, P < 0.001). No significant difference in all‐cause mortality was observed between the ETV and TDF groups (log–rank test, P = 0.69). After propensity score matching, no significant differences in all‐cause, liver‐related, or non‐liver‐related mortality were observed between the two groups. Conclusions: Long‐term outcomes of all‐cause mortality and liver‐related and non‐liver‐related mortality did not differ between patients treated with ETV and those receiving TDF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
328. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
- Author
-
Toyoda, Hidenori, Tada, Toshifumi, Uojima, Haruki, Nozaki, Akito, Chuma, Makoto, Takaguchi, Koichi, Hiraoka, Atsushi, Abe, Hiroshi, Itobayashi, Ei, Matsuura, Kentaro, Atsukawa, Masanori, Watanabe, Tsunamasa, Shimada, Noritomo, Nakamuta, Makoto, Kojima, Motoyuki, Tsuji, Kunihiko, Mikami, Shigeru, Ishikawa, Toru, Yasuda, Satoshi, and Tsutsui, Akemi
- Subjects
- *
HEPATOCELLULAR carcinoma , *JAPANESE people , *CHRONIC hepatitis C , *PREDICTION models , *HEPATITIS C virus - Abstract
Background and Aim: While several predictive models for the development of hepatocellular carcinoma (HCC) have been proposed, including those for patients with chronic hepatitis C virus (HCV) infection who have achieved sustained virologic response (SVR), the best model may differ between regions. We compared the ability of six reported models to stratify the risk of post‐SVR HCC in Japan, where rigorous surveillance and early detection of HCC is common. Methods: A total of 6048 patients with no history of HCC who achieved SVR by oral direct‐acting antiviral drugs were enrolled in this nationwide study. Patients continued HCC surveillance every 6 months after SVR. The incidence of post‐SVR HCC was compared between risk groups using the aMAP score, FIB‐4 index, Tahata model, GAF4 criteria, GES score, and ADRES score. Results: During the observation period with a median duration of 4.0 years after SVR, post‐SVR HCC developed in 332 patients (5.5%). All six models performed significantly at stratifying the incidence of HCC. However, Harrell's C‐index was below 0.8 for all models (range, 0.660–0.748), indicating insufficient stratification ability. Conclusion: Although all six proposed models demonstrated a good ability to predict the development of post‐SVR HCC, their ability to stratify the risk of post‐SVRHCC was unsatisfactory. Further studies are necessary to identify the best model for assessing the risk of post‐SVR HCC in regions where early detection of HCC is common. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
329. Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
- Author
-
Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Yokohama, Keisuke, and Nishikawa, Hiroki
- Subjects
- *
ATEZOLIZUMAB , *HEPATOCELLULAR carcinoma , *BEVACIZUMAB , *OLDER patients , *TERMINATION of treatment - Abstract
Aim: Elderly patients are believed to have a reduced immune capacity, which may make immunotherapy less effective. The aim of this study was to compare the therapeutic outcome of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) for advanced hepatocellular carcinoma (HCC) in patients aged 80 years and older. Methods: From March 2018 to July 2022, 170 and 92 elderly patients who received LEN and Atez/Bev as first‐line treatment, respectively, were retrospectively analyzed. Results: The median ages of the Atez/Bev and LEN groups were 83.0 (8.01–86.0) and 83.0 (82.0–86.0) years (p = 0.3), respectively. Men accounted for approximately 70% of the patients in both groups. The objective response rate was 35.9% in the LEN group and 33.7% in the Atez/Bev group (p = 0.8), whereas the disease control rates in the LEN and Atez/Bev groups were 62.9% and 63.0%, respectively (p = 1.0). The median progression‐free survival (PFS) in the LEN and Atez/Bev groups was 6.3 and 7.2 months, respectively, which were not significantly different (p = 0.2). The median overall survival (OS) was 17.9 months in the LEN group and 14.0 months in the Atez/Bev group. This difference was not statistically significant (p = 0.7). In multivariate analyses, the choice of treatment (LEN vs. Atez/Bev) showed no association with PFS or OS. The Atez/Bev group had a significantly higher rate of postprogression treatment (59.0% vs. 35.7%, p = 0.01) and a lower rate of discontinuation due to adverse events (69 [40.6%] vs. 19 [20.7%], p < 0.001) compared to the LEN group. Conclusions: Atezolizumab plus bevacizumab showed comparable effectiveness to LEN in HCC patients aged 80 years and older. Given the results of postprogression treatment and discontinuation due to adverse events, Atez/Bev could serve as a first‐line treatment even for elderly HCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
330. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma.
- Author
-
Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, and Kakizaki, Satoru
- Subjects
- *
HEPATOCELLULAR carcinoma , *BEVACIZUMAB , *ATEZOLIZUMAB , *SURVIVAL rate , *LIVER cancer - Abstract
Background & Aims: The study goal was to compare the outcomes of patients with intermediate‐stage (Barcelona Clinic Liver Cancer [BCLC]‐B) hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) or lenvatinib (LEN) as first‐line systemic therapy. Methods: A total of 358 patients with BCLC‐B HCC treated with Atezo/Bev (n = 177) or LEN (n = 181) as first‐line systemic therapy were included. Results: The median progression‐free survival (PFS) times in the Atezo/Bev and LEN groups were 10.8 months (95% confidence interval [CI], 7.8–12.6) and 7.3 months (95% CI, 6.3–8.5), respectively (p =.019). In the propensity score‐matched cohort, the median PFS times in the Atezo/Bev (n = 151) and LEN (n = 151) groups were 10.2 months (95% CI, 7.0–12.3) and 6.9 months (95% CI, 5.9–8.1), respectively (p =.020). Restricted mean survival times of PFS were significantly higher in the Atezo/Bev group than in the LEN group at landmarks of 12 and 18 months (p =.031 and.012, respectively). In a subgroup analysis of patients with HCC beyond the up‐to‐seven criteria, the median PFS times in the Atezo/Bev (n = 134) and LEN (n = 117) groups were 10.5 months (95% CI, 7.0–11.8) and 6.3 months (95% CI, 5.5–7.3), respectively (p =.044). Conclusions: The use of Atezo/Bev as first‐line systemic therapy in patients with BCLC‐B HCC is expected to result in good PFS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
331. Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach.
- Author
-
Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Yokohama, Keisuke, and Nishikawa, Hiroki
- Subjects
- *
ATEZOLIZUMAB , *BEVACIZUMAB , *REGRESSION analysis , *NONLINEAR regression , *PROPENSITY score matching - Abstract
Aim: This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. Methods: We included 526 patients who received Atez/Bev and 731 who received LEN March 2018 and July 2022 in this study. We conducted a 1:1 propensity‐score‐matched analysis and identified 324 patients in each group for inclusion in the present analysis. Nonlinear mixed‐effects regression models were employed, allowing for the evaluation and inclusion of cases where treatment was interrupted due to disease progression, adverse events, or loss to follow‐up. These models were used to compare the ALBI score between the Atez/Bev and LEN groups. Results: Following propensity score matching, the mean ALBI scores in the Atez/Bev and LEN groups were −2.41 ± 0.40 and −2.44 ± 0.42 at baseline, and −2.17 ± 0.56 and −2.19 ± 0.58 at 12 weeks, respectively. Although the ALBI score significantly worsened during treatment in both groups (p < 0.001), there was no significant difference in the rate of ALBI score deterioration between the groups (p = 0.06). Subgroup analyses showed that LEN‐treated patients with BCLC advanced stage (p = 0.02) and those who initially received the full dose (p < 0.001) had a significantly greater worsening of ALBI score compared to Atez/Bev. Conclusions: Using a nonlinear mixed‐effects regression approach, which allowed for the inclusion of cases with treatment interruption, we found no significant difference in the trend of liver function deterioration between the Atez/Bev and LEN groups. Caution should be exercised for LEN‐treated patients with BCLC advanced stage or those receiving the full dose of LEN. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
332. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices.
- Author
-
Tada, Fujimasa, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, and Shimada, Noritomo
- Subjects
- *
HEPATOCELLULAR carcinoma , *BEVACIZUMAB , *ATEZOLIZUMAB , *PORTAL vein , *PLATELET count - Abstract
Background: Bevacizumab inhibits vascular endothelial growth factor-A (VEGF-A), though is known to increase bleeding risk as an adverse event (AE). This study examined whether atezolizumab/bevacizumab (Atez/Bev) for unresectable hepatocellular carcinoma (uHCC) can be used for patients with esophageal–gastric varices (EGV). Methods: From October 2020 to December 2022, 506 uHCC patients (median 74 years) underwent an upper gastrointestinal endoscopy examination were enrolled, after exclusion of those with portal vein tumor thrombus (PVTT). Patients with EGV (≧ F1) were defined as EGV positive, and the cohort was divided into non-EGV (n = 355) and EGV (n = 151). Before introducing Atez/Bev, endoscopic treatment was performed, when necessary. Prognosis was evaluated, retrospectively. Results: The EGV group had significantly worse hepatic function, lower platelet count, elevated alpha-fetoprotein, and lower rate of extrahepatic metastasis, and lower rate of first-line use (each P < 0.05) than the other. However, progression-free survival (PFS) was also not a significantly difference between the EGV and non-EGV groups in analyses with (PFS rate at 6/12/18 months: 60%/38%/30% vs. 65%/46%/34%, P = 0.29) or without inverse probability weighting adjustment [median: 10.6 months (95% CI 8.3–14.0) vs. 10.5 months (95% CI 7.8–13.7), P = 0.79]. As for AEs, diarrhea was more frequent in the EGV group (≧ G3: 2.0% vs. 0.3%, P = 0.036), while no significant difference was noted for EGV hemorrhage (≧ G3: 1.3% vs. 0.6%, P = 0.345). Of 28 patients who underwent endoscopic treatments before introducing Atez/Bev, none showed EGV-associated hemorrhage. Conclusions: Atez/Bev might be an effective therapeutic option in patients with EGV, when appropriate endoscopic treatment for EGV is performed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
333. Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
- Author
-
Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, and Kakizaki, Satoru
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *THERAPEUTIC use of antineoplastic agents , *LIVER tumors , *COMBINATION drug therapy , *LIVER , *RADIO frequency therapy , *ANTINEOPLASTIC agents , *MONOCLONAL antibodies , *RETROSPECTIVE studies , *CATHETER ablation , *MAGNETIC resonance imaging , *PROTEIN-tyrosine kinase inhibitors , *LIVER diseases , *TREATMENT effectiveness , *TREATMENT failure , *BEVACIZUMAB , *PROGRESSION-free survival , *HEPATOCELLULAR carcinoma , *OVERALL survival , *IMMUNOTHERAPY - Abstract
Introduction: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is an important clinical issue. The present study aimed to elucidate the potential of lenvatinib as a second-line treatment option after Atez/Bev failure. Methods: From 2020 to 2022, 101 patients who received lenvatinib as second-line treatment were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D = 1:35:61:4), while 29 treated with another molecular targeting agent (MTA) during the period as second-line treatment were enrolled as controls. The therapeutic efficacy of lenvatinib given as second-line treatment was retrospectively evaluated. Results: Median progression-free survival/median overall survival for all patients was 4.4/15.7 months and for those with Child-Pugh A was 4.7 months/not-reached. When prognosis was compared with patients who received another MTA, there was no significant difference for PFS (3.5 months, p = 0.557) or OS (13.6 months, p = 0.992), and also no significant differences regarding clinical background factors. mRECIST findings showed that objective response and disease control rates in patients treated with lenvatinib were 23.9% and 70.4%, respectively (CR:PR:SD:PD = 3:14:33:21), while those shown by RECIST, ver. 1.1, were 15.4% and 66.2%, respectively (CR:PR:SD:PD = 1:10:36:24). Adverse events (any grade ≥10%) were appetite loss (26.7%) (grade 1:2:3 = 2:15:10), general fatigue (21.8%) (grade 1:2:3 = 3:13:6), protein in urine (16.8%) (grade 1:2:3 = 0:4:13), and hypertension (13.9%) (grade 1:2:3 = 1:8:5). Conclusion: Although lenvatinib treatment might not provide a pseudo-combination immunotherapy effect following Atez/Bev failure, lenvatinib when used as second-line treatment after Atez/Bev failure might be expected to be comparable as compared to its use as first-line treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
334. Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
- Author
-
Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, and Kakizaki, Satoru
- Subjects
- *
NUTRITIONAL assessment , *BEVACIZUMAB , *ATEZOLIZUMAB , *CANCER chemotherapy , *SERUM albumin - Abstract
Aim: The present study focused on Geriatric Nutritional Risk Index (GNRI), which is based on bodyweight and serum albumin, and known as an easy‐to‐use nutritional assessment tool in clinical settings, to elucidate the prognostic predictive ability of GNRI in patients treated with atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC). Methods: A total of 525 HCC patients treated with Atez/Bev, based on their classification of unsuitable status for curative treatments and/or transarterial catheter chemoembolization, were enrolled (Child–Pugh A:B:C = 484:40:1, Barcelona Clinic Liver Cancer stage 0:A:B:C:D = 7:25:192:283:18). Prognosis was evaluated retrospectively using GNRI. Results: Atez/Bev was used in 338 of the present cohort as first‐line systemic chemotherapy (64.4%). Median progression‐free survival based on GNRI indicating normal, mild decline, moderate decline, and severe decline was 8.3, 6.7, 5.3, and 2.4 months, respectively, whereas median overall survival was 21.4, 17.0, 11.5. and 7.3 months, respectively (both p < 0.001). The concordance index (c‐index) values of GNRI for predicting prognosis (progression‐free survival/overall survival) were superior to those of Child–Pugh class and albumin‐bilirubin grade (0.574/0.632 vs. 0.527/0.570 vs. 0.565/0.629). As a subanalysis, muscle volume loss was observed in 37.5% of 256 patients with computed tomography data available. Along with GNRI decline, frequency of muscle volume loss became progressively larger (normal vs. mild vs. moderate vs. severe = 17.6% vs. 29.2% vs. 41.2% vs. 57.9%, p < 0.001), and a GNRI value of 97.8 was predictive of its occurrence (AUC 0.715, 95% CI 0.649–0.781; specificity/sensitivity = 0.644/0.688). Conclusion: These findings indicate that GNRI is an effective nutritional prognostic tool for predicting prognosis and muscle volume loss complication in HCC patients treated with Atez/Bev. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
335. Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
- Author
-
Ohama, Hideko, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, and Kakizaki, Satoru
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *CONFIDENCE intervals , *RETROSPECTIVE studies , *PROTEIN-tyrosine kinase inhibitors , *DESCRIPTIVE statistics , *RESEARCH funding , *PROGRESSION-free survival , *BEVACIZUMAB , *HEPATOCELLULAR carcinoma , *OVERALL survival - Abstract
Introduction: Systemic treatment is generally recommended for Child-Pugh (CP) A status patients with an unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate differences regarding therapeutic efficacy between lenvatinib (LEN), a multi-molecular target agent, and atezolizumab plus bevacizumab (Atez/Bev), a newly developed immune-combined therapeutic regimen for CP-B patients affected by uHCC. Methods: From April 2018 to July 2022, 128 patients with uHCC treated with Atez/Bev (n = 29) or LEN (n = 99) as the initial systemic treatment were enrolled (median age 71 years; males 97; CP score 7:8:9 = 94:28:6; median albumin-bilirubin score −1.71). Therapeutic response was evaluated using RECIST, version 1.1. Clinical features and prognosis were retrospectively examined. Results: There were no significant differences between the Atez/Bev and LEN groups in regard to best response (CR:PR:SD:PD = 0:5:12:7 vs. 5:22:25:20, p = 0.415), progression-free survival (PFS) (median 5.0 [95% CI: 2.4–7] vs. 5.5 [95% CI: 3.4–7.9] months, p = 0.332), or overall survival (OS) (5.8 [95% CI: 4.3–11] vs. 8.8 [95% CI: 6.1–12.9] months, p = 0.178). Adverse events (any grade/≥ grade 3) were observed in 72.4%/17.2% (n = 21/5) of patients treated with Atez/Bev and 78.8%/25.3% (n = 78/25) of those treated with LEN (p = 0.46/0.46). Discussion: This retrospective study found no significant differences regarding PFS or OS between CP-B patients given Atez/Bev or LEN as initial systemic treatment for uHCC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
336. Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
- Author
-
Tanaka, Kazunari, Tsuji, Kunihiko, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, and Shimada, Noritomo
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *THERAPEUTIC use of antineoplastic agents , *CANCER patient psychology , *RESEARCH , *ALPHA fetoproteins , *PREDICTIVE tests , *CONFIDENCE intervals , *RETROSPECTIVE studies , *PROTEIN precursors , *PROTHROMBIN , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *BEVACIZUMAB , *TUMOR markers , *PREDICTION models , *HEPATOCELLULAR carcinoma - Abstract
Simple Summary: Atezolizumab plus bevacizumab (Atez/Bev) is the first-line treatment for unresectable advanced hepatocellular carcinoma (HCC). The tumor markers (TMs) for HCC include alpha-fetoprotein (AFP), fucosylated alpha-fetoprotein (AFP-L3), and des-gamma carboxyprothrombin (DCP). A TM score combining these markers has been reported to be useful in predicting HCC prognosis. This retrospective study aimed to evaluate the ability of this previously reported TM score involving AFP, AFP-L3, and DCP as TMs in predicting prognosis and therapeutic efficacy in HCC patients administered Atez/Bev as first-line treatment. The TM score was found to be effective in stratifying overall survival and progression-free survival in 371 patients with unresectable advanced HCC treated with Atez/Bev. The TM score proved to be a simple and useful prognostic marker and therapeutic efficacy indicator for advanced HCC patients administered Atez/Bev as first-line treatment. Aim: This study aimed to evaluate the ability of a previously reported tumor marker (TM) score involving alpha-fetoprotein (AFP), fucosylated AFP (AFP-L3), and des gamma-carboxy prothrombin (DCP) as TMs in predicting the prognosis and therapeutic efficacy in hepatocellular carcinoma (HCC) patients administered atezolizumab plus bevacizumab (Atez/Bev) as first-line treatment. Materials/Methods: The study period covered September 2020 to December 2022 and involved 371 HCC patients treated with Atez/Bev. The values of the TMs AFP, AFP-L3, and DCP were measured upon introducing Atez/Bev. Elevations in the values of AFP (≥100 ng/mL), AFP-L3 (≥10%), and DCP (≥100 mAU/mL) were considered to indicate a positive TM. The number of positive TMs was summed up and used as the TM score, as previously proposed. Hepatic reserve function was assessed using the modified albumin–bilirubin grade (mALBI). Predictive values for prognosis were evaluated retrospectively. Results: A TM score of 0 was shown in 81 HCC patients (21.8%), 1 in 110 (29.6%), 2 in 112 (29.9%), and 3 in 68 (18.3%). The median overall survival (OS) times for TM scores 0, 1, 2, and 3 were not applicable [NA] (95% CI NA-NA), 24.0 months (95% CI 17.8-NA), 16.7 months (95% CI 17.8-NA), and NA (95% CI 8.3-NA), respectively (p < 0.001). The median progression-free survival (PFS) times for TM scores 0, 1, 2, and 3 were 16.5 months (95% CI 8.0-not applicable [NA]), 13.8 months (95% CI 10.6–21.3), 7.7 months (95% CI 5.3–8.9), and 5.8 months (95% CI 3.0–7.6), respectively (p < 0.001). OS was well stratified in mALBI 1/2a and mALBI 2a/2b. PFS was well stratified in mALBI 2a/2b, but not in mALBI 1/2a. Conclusions: The TM score involving AFP, AFP-L3, and DCP as TMs was useful in predicting the prognosis and therapeutic efficacy in terms of OS and PFS in HCC patients administered Atez/Bev as first-line treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
337. Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab.
- Author
-
Nouso, Kazuhiro, Shiota, Shohei, Fujita, Rio, Wakuta, Akiko, Kariyama, Kazuya, Hiraoka, Atsushi, Atsukawa, Masanori, Tani, Joji, Tada, Toshifumi, Nakamura, Shinichiro, Tajiri, Kazuto, Kaibori, Masaki, Hirooka, Masashi, Itobayashi, Ei, Kakizaki, Satoru, Naganuma, Atsushi, Ishikawa, Toru, Hatanaka, Takeshi, Fukunishi, Shinya, and Tsuji, Kunihiko
- Subjects
- *
ATEZOLIZUMAB , *BEVACIZUMAB , *ENTEROBACTERIACEAE , *ORAL drug administration , *BUTYRIC acid - Abstract
Aim: Multiple studies have revealed the correlation between gut microbiome and the response to checkpoint inhibitors (CPIs) in patients with cancer, and oral administration of butyrate‐producing enterobacteria has been reported to enhance the efficacy of CPIs. However, the effects of enterobacteria on patients with hepatocellular carcinoma (HCC) are not well understood. Methods: In this retrospective multicenter study, we enrolled 747 patients with advanced HCC, treated with atezolizumab and bevacizumab combination therapy. Tumor response, survival, and adverse effects were compared between 99 patients who ingested drugs containing butyric acid‐producing enterobacteria (butyric acid group) and the remaining patients (control group). Results: Objective response and disease control rates in butyric acid group (29.7% and 77.8%, respectively) were higher than those in the control group (26.4% and 72.7%, respectively). However, the differences were not statistically significant (p = 0.543 and p = 0.222, respectively). No difference in median survival time was observed between the two groups (20.0 months and 21.4 months, respectively; p = 0.789), even after matching the backgrounds of the patients with propensity scores (p = 0.714). No adverse effects occurred upon the administration of butyrate‐producing bacteria. However, proteinuria (41.4% vs. 30.9%; p = 0.041), fever (17.2% vs. 10.2%, p = 0.036), and diarrhea (15.2% vs. 6.2%; p = 0.001) occurred more frequently in the butyric acid group. Conclusion: Butyrate‐producing bacteria does not enhance the efficacy of atezolizumab–bevacizumab combination therapy in patients with HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
338. Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
- Author
-
Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, and Shimada, Noritomo
- Subjects
- *
PROTON pump inhibitors , *HEPATOCELLULAR carcinoma , *ATEZOLIZUMAB , *BEVACIZUMAB , *TREATMENT effectiveness - Abstract
Aim: This retrospective study aimed to investigate the impact of proton pump inhibitor treatment (PPI) and antibiotic treatment on the therapeutic outcomes of hepatocellular carcinoma (HCC) patients receiving atezolizumab and bevacizumab (Atez/Bev). Methods: The present study included a total of 441 HCC patients who were treated with Atez/Bev in 20 Japanese institutions from September 2020 to April 2022. We adopted the inverse probability of treatment weight to adjust for imbalance in the baseline characteristics of patients with and without PPI treatment as well as patients with and without antibiotic treatment. Results: The progression‐free survival (PFS) and overall survival (OS) of patients with and without PPI treatment did not differ to a statistically significant extent. In the weighted cohort, the difference in PFS and OS between the patients with and without PPI did not reach statistical significance (median PFS, 7.0 vs. 6.5 months, p = 0.07; 1‐year survival rate 66.3% and 73.8%, p = 0.9). The PFS and OS in patients with antibiotic treatment were worse in comparison to patients without antibiotic treatment (median PFS, 3.8 vs. 7.0 months, p = 0.007; 1‐year survival rate 58.8% and 70.3%, p = 0.01). In the weighted cohort, the PFS and OS of the two groups did not differ to a statistically significant extent (median PFS, 3.8 vs. 6.7 months, p = 0.2; 1‐year survival rate, 61.8% and 71.0%, p = 0.6). Conclusions: The therapeutic outcomes of Atez/Bev in HCC patients did not differ between patients with and without PPI treatment or between patients with and without antibiotic treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
339. Impact of first‐line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
- Author
-
Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, and Kakizaki, Satoru
- Subjects
- *
BEVACIZUMAB , *ATEZOLIZUMAB , *PROGRESSION-free survival , *SURVIVAL analysis (Biometry) , *ADVERSE health care events , *HEPATOCELLULAR carcinoma - Abstract
Background and Aim: The study goal was to compare the outcomes of patients with unresectable hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) as either first‐ or later‐line systemic therapy. Methods: A total of 430 patients with HCC treated with Atezo/Bev at 22 institutions in Japan were included. Patients treated with Atezo/Bev as first‐line therapy for HCC were defined as the first‐line group (n = 268) while those treated with Atezo/Bev as second‐ or later‐line therapy were defined as the later‐line group (n = 162). Results: The median progression‐free survival times in the first‐ and later‐line groups were 7.7 months (95% confidence interval [CI], 6.7–9.2) and 6.2 months (95% CI, 5.0–7.7) (P = 0.021). Regarding treatment‐related adverse events, hypertension of any grade was more common in the first‐line group than in the later‐line group (P = 0.025). Analysis adjusted by inverse probability weighting, including patient and HCC characteristics, showed that the later‐line group (hazard ratio, 1.304; 95% CI, 1.006–1.690; P = 0.045) was significantly associated with progression‐free survival. In patients with Barcelona Clinic Liver Cancer stage B, the median progression‐free survival times in the first‐ and later‐line groups were 10.5 months (95% CI, 6.8–13.8) and 6.8 months (95% CI, 5.0–9.4) (P = 0.021). Among patients with a history of lenvatinib therapy, the median progression‐free survival times in the first‐ and later‐line groups were 7.7 months (95% CI, 6.3–9.2) and 6.2 months (95% CI, 5.0–7.7) (P = 0.022). Conclusion: The use of Atezo/Bev as first‐line systemic therapy in patients with HCC is expected to prolong survival. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
340. Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
- Author
-
Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Kariyama, Kazuya, Tani, Joji, Hirooka, Masashi, Takaguchi, Koichi, Atsukawa, Masanori, Fukunishi, Shinya, Itobayashi, Ei, Tsuji, Kunihiko, Tajiri, Kazuto, Ochi, Hironori, Ishikawa, Toru, Yasuda, Satoshi, Ogawa, Chikara, Toyoda, Hidenori, Hatanaka, Takeshi, Nishimura, Takashi, and Kakizaki, Satoru
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *NUTRITIONAL assessment , *CONFIDENCE intervals , *MULTIVARIATE analysis , *LOG-rank test , *RETROSPECTIVE studies , *FISHER exact test , *RESEARCH funding , *DESCRIPTIVE statistics , *CHI-squared test , *BEVACIZUMAB , *HEPATOCELLULAR carcinoma , *NUTRITIONAL status - Abstract
Introduction: This study investigated the relationship between nutritional status, as determined by the prognostic nutritional index (PNI), and outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/bev). Methods: The study analyzed 485 HCC patients treated with Atez/bev. Results: There were 342 patients with a low PNI (<47) and 143 patients with a high PNI (≥47). The median follow-up duration was 9.4 (6.0–14.3) months. Multivariate Cox hazards analysis showed that an α-fetoprotein level ≥100 ng/mL (hazard ratio (HR), 2.217; 95% confidence interval (CI), 1.588–3.095; p < 0.001), and PNI ≥47 (HR, 0.333; 95% CI, 0.212–0.525; p < 0.001) were independently associated with overall survival. Multivariate analysis showed that an α-fetoprotein level ≥100 ng/mL (HR, 1.690; 95% CI, 1.316–2.170; p < 0.001) and PNI ≥47 (HR, 0.696; 95% CI, 0.528–0.918; p = 0.010) were independently associated with progression-free survival. Cumulative overall and progression-free survival rates differed significantly by PNI (p < 0.001 and p < 0.002, respectively). In a subgroup analysis using inverse probability weighting adjustment in patients with albumin-bilirubin grade 1 (n = 173), univariate Cox hazards analysis showed that a PNI ≥47 (HR, 0.502; 95% CI, 0.260–0.991; p = 0.047) was significantly associated with overall survival. Spline curve analysis revealed that a PNI of approximately 34–48 is an appropriate cutoff for predicting good overall and progression-free survival. Conclusion: The PNI, a biomarker of nutritional status, can predict prognosis in patients with HCC treated with Atez/bev, even those who are considered to have a good prognosis due to good liver function. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
341. Galectin-9 in Gastroenterological Cancer.
- Author
-
Morishita, Asahiro, Oura, Kyoko, Tadokoro, Tomoko, Shi, Tingting, Fujita, Koji, Tani, Joji, Atsukawa, Masanori, and Masaki, Tsutomu
- Subjects
- *
CELL receptors , *T cells , *CANCER cells , *GASTROINTESTINAL cancer , *CELL death - Abstract
Immunochemotherapy has become popular in recent years. The detailed mechanisms of cancer immunity are being elucidated, and new developments are expected in the future. Apoptosis allows tissues to maintain their form, quantity, and function by eliminating excess or abnormal cells. When apoptosis is inhibited, the balance between cell division and death is disrupted and tissue homeostasis is impaired. This leads to dysfunction and the accumulation of genetically abnormal cells, which can contribute to carcinogenesis. Lectins are neither enzymes nor antibodies but proteins that bind sugar chains. Among soluble endogenous lectins, galectins interact with cell surface sugar chains outside the cell to regulate signal transduction and cell growth. On the other hand, intracellular lectins are present at the plasma membrane and regulate signal transduction by regulating receptor–ligand interactions. Galectin-9 expressed on the surface of thymocytes induces apoptosis of T lymphocytes and plays an essential role in immune self-tolerance by negative selection in the thymus. Furthermore, the administration of extracellular galectin-9 induces apoptosis of human cancer and immunodeficient cells. However, the detailed pharmacokinetics of galectin-9 in vivo have not been elucidated. In addition, the cell surface receptors involved in galectin-9-induced apoptosis of cancer cells have not been identified, and the intracellular pathways involved in apoptosis have not been fully investigated. We have previously reported that galectin-9 induces apoptosis in various gastrointestinal cancers and suppresses tumor growth. However, the mechanism of galectin-9 and apoptosis induction in gastrointestinal cancers and the detailed mechanisms involved in tumor growth inhibition remain unknown. In this article, we review the effects of galectin-9 on gastrointestinal cancers and its mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
342. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
- Author
-
Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, and Kakizaki, Satoru
- Subjects
- *
BEVACIZUMAB , *ATEZOLIZUMAB , *MULTIVARIATE analysis , *FATIGUE (Physiology) , *PROGRESSION-free survival , *CANCER fatigue - Abstract
Aim: To investigate the possible correlation between the development of adverse events (AEs) and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev). Methods: A total of 286 patients with unresectable HCC treated with Atez/Bev as first‐line systematic therapy were included. Results: Regarding treatment‐related AEs, decreased appetite of any grade, proteinuria of any grade, and fatigue of any grade were found with a frequency of ≥20%. Multivariate analysis adjusted for immune‐related liver injury, immune‐related endocrine dysfunction, proteinuria, fatigue, decreased appetite, hypertension, sex, age, Eastern Cooperative Oncology Group performance status, HCC etiology, HCC stage, Child–Pugh score, and α‐fetoprotein showed that hypertension of any grade (hazard ratio [HR], 0.527; 95% confidence interval [CI], 0.326–0.854; p = 0.009) and α‐fetoprotein ≥100 ng/ml (HR, 1.642; 95% CI, 1.111–2.427; p = 0.013) were independently associated with progression‐free survival. Multivariate analysis adjusted for the same AEs showed that fatigue (HR, 2.354; 95% CI, 1.299–4.510; p = 0.010) was independently associated with overall survival. Median progression‐free survival was 6.5 months (95% CI, 5.2–8.1) in patients without hypertension of any grade and 12.6 months (95% CI, 6.7–not available) in patients with hypertension of any grade (p = 0.035). The overall survival was significantly shorter in patients in whom treatment‐related fatigue of any grade was observed (p < 0.001). Regarding response rates, the disease control rate of patients who developed treatment‐related hypertension (94.2%) was significantly higher than those who did not (79.1%) (p = 0.009). Conclusions: Treatment‐related hypertension is associated with good outcomes in patients with HCC treated with Atez/Bev. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
343. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
- Author
-
Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Kariyama, Kazuya, Tani, Joji, Hirooka, Masashi, Takaguchi, Koichi, Atsukawa, Masanori, Fukunishi, Shinya, Itobayashi, Ei, Tsuji, Kunihiko, Tajiri, Kazuto, Ochi, Hironori, Ishikawa, Toru, Yasuda, Satoshi, Ogawa, Chikara, Toyoda, Hidenori, Hatanaka, Takeshi, Nishimura, Takashi, and Kakizaki, Satoru
- Subjects
- *
ATEZOLIZUMAB , *BEVACIZUMAB , *SURVIVAL rate , *C-reactive protein , *AKAIKE information criterion - Abstract
Aim: Recently, the neo‐Glasgow prognostic score (GPS), a composite biomarker determined by the C‐reactive protein level and albumin–bilirubin grade, was developed to predict outcomes in hepatocellular carcinoma (HCC) patients who undergo hepatic resection. The present research investigated whether the neo‐GPS could predict prognosis in HCC patients treated with atezolizumab plus bevacizumab (Atez/Bev). Methods: A total of 421 patients with HCC who were treated with Atez/Bev were investigated. Results: Multivariate Cox hazards analysis showed that a GPS of 1 (hazard ratio (HR), 1.711; 95% confidence interval (CI), 1.106–2.646) and a GPS of 2 (HR, 4.643; 95% CI, 2.778–7.762) were independently associated with overall survival. Conversely, multivariate Cox hazards analysis showed that a neo‐GPS of 1 (HR, 3.038; 95% CI, 1.715–5.383) and a neo‐GPS of 2 (HR, 5.312; 95% CI, 2.853–9.890) were also independently associated with overall survival in this cohort. Additionally, cumulative overall survival rates differed significantly by GPS and neo‐GPS (p < 0.001). The neo‐GPS, compared with the GPS, had a lower Akaike information criterion (1207 vs. 1,211, respectively) and a higher c‐index (0.677 vs. 0.652, respectively) regarding to overall survival. In a subgroup analysis of patients considered to have a good prognosis as confirmed using a Child–Pugh score of 5 (p = 0.001), a neutrophil‐to‐lymphocyte ratio <3 (p = 0.001), or an α‐fetoprotein level < 100 ng/mL (p < 0.001), those with a high neo‐GPS (≥1) had a statistically poorer overall survival than those with a low neo‐GPS. Conclusions: The neo‐GPS can predict prognosis in advanced unresectable HCC patients treated with Atez/Bev. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
344. Cell‐free and concentrated ascites reinfusion therapy versus large‐volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study.
- Author
-
Hanai, Tatsunori, Kawaratani, Hideto, Nagano, Junji, Suii, Hirokazu, Sakamaki, Akira, Arase, Yoshitaka, Nakanishi, Hiroyuki, Kogiso, Tomomi, Okubo, Tomomi, Miwa, Takao, Shimizu, Shogo, Hige, Shuhei, Atsukawa, Masanori, Shimizu, Masahito, Kurosaki, Masayuki, Terai, Shuji, Kagawa, Tatehiro, Tokushige, Katsutoshi, and Yoshiji, Hitoshi
- Subjects
- *
ASCITES , *LONGITUDINAL method , *PARACENTESIS , *SCIENTIFIC observation , *QUALITY of life - Abstract
Aim: Cell‐free and concentrated ascites reinfusion therapy (CART) and large‐volume paracentesis (LVP) with albumin infusion are useful for managing refractory ascites (RA). However, it remains unclear which therapy is more effective in patients with cirrhosis with RA. Methods: From June 2018 to March 2022, 25 patients with RA treated with CART or LVP with albumin infusion were enrolled in this multicenter prospective observational study to investigate the number of abdominal paracenteses, albumin preparations used, and drainage volume during an 8‐week observation period. Results: Among all patients at entry (median age, 63 years; 52% men; 60% Child–Pugh B and 40% Child–Pugh C), 92% were treated with furosemide (median, 20 mg/day), 92% with spironolactone (25 mg/day), and all with tolvaptan (7.5 mg/day). Patients with RA had a poor health‐related quality of life (HRQOL) and prominent ascites‐related symptoms. Four of the 20 eligible patients were treated with CART, 11 with LVP with albumin infusion, and five with their combination. The median number of paracenteses, total drainage volume, and albumin infusions were 1.5, 7.4 L, and 0, respectively, in the CART group; 5.0, 22.0 L, and 5.0, respectively, in the LVP group; and 5.0, 30.0 L, and 5.0, respectively in their combination group. The treatment effects did not differ significantly among the three groups regarding weight loss, liver function, renal function, electrolytes, and HRQOL. However, patients treated with CART had fewer paracenteses and albumin infusions than those treated with LVP. Conclusions: CART and LVP have comparable therapeutic efficacy for RA in patients with cirrhosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
345. Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study.
- Author
-
Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, and Shimada, Noritomo
- Subjects
- *
VIRUS diseases , *HEPATOCELLULAR carcinoma , *ATEZOLIZUMAB , *BEVACIZUMAB , *PROPENSITY score matching - Abstract
Aim: This study compared the efficacy and safety of atezolizumab and bevacizumab (Atez/Bev) in patients with viral and non‐viral infection in clinical settings. Methods: We conducted the retrospective cohort study of 323 BCLC stage B or C hepatocellular carcinoma (HCC) patients with Child‐Pugh class A, and a performance status of 0 or 1 who started Atez/Bev from September 2020 to December 2021 at 22 institutions in Japan. Patients with viral infection was defined as those who were either serum anti‐HCV‐ Ab or HBs‐Ag‐positive, while patients with non‐viral infection was defined as those who were both serum anti‐HCV Ab‐ and HBs‐Ag‐negative. We constructed a propensity‐score‐matched cohort to minimize the risk of observable potential confounders. Results: Propensity score matching produced 126 matched pairs for patients with viral versus non‐viral infection. After matching, the significant differences in baseline demographic features did not exist between the two groups. The objective response rate was 20.6% and 24.6% in viral‐ and non‐viral‐related HCC patients, respectively, without a significant difference (p = 0.55). The disease control rate was not also significantly different (68.3% vs 69.0%, p = 1.00). The median progression‐free survival was 7.0 months (95% confidence interval [CI] 6.0–9.6) and 6.2 months (95% CI 5.1–7.8) in patients with viral and non‐viral infection, and the 12‐month survival rates were 65.5% (95% CI 50.8–76.8) and 71.7% (95% CI 57.3–81.9) in those with viral and non‐viral infection, respectively, which were not significantly different (p = 0.33, p = 0.38). No significant difference in treatment‐related adverse events was found between the two groups. Conclusions: Our etiology‐based study demonstrated that Atez/Bev showed good efficacy and safety for HCC patient with non‐viral infection as well as those with viral infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
346. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.
- Author
-
Hatanaka, Takeshi, Naganuma, Atsushi, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, and Shimada, Noritomo
- Subjects
- *
HEPATOCELLULAR carcinoma , *ATEZOLIZUMAB , *BEVACIZUMAB , *NEUTROPHIL lymphocyte ratio , *LACTATE dehydrogenase - Abstract
Aim: This study investigated whether or not the hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC‐GRIm‐Score) serves as a prognostic indicator for HCC patients treated with atezolizumab and bevacizumab (Atez/Bev). Methods: A total of 405 HCC patients who received Atez/Bev from September 2020 to January 2022 at 22 different institutions were included in this retrospective study. The HCC‐GRIm score was based on the combination of the albumin level (<3.5 g/L = 1 point), lactate dehydrogenase (≥245 U/L = 1 point), neutrophil‐to‐lymphocyte ratio (≥4.8 = 1 point), aspartate aminotransferase‐to‐alanine aminotransferase ratio (≥1.44 = 1 point), and total bilirubin level (≥1.3 mg/dl = 1 point). Patients were divided into the low‐score group (0, 1, or 2 points) and the high‐score group (3, 4, or 5 points). Results: There were 89 (22.0%), 141 (34.8%), 106 (26.2%), 49 (12.1%), 16 (4.0%), and 4 (1.0%) patients with scores of 0, 1, 2, 3, 4, 5, respectively. The progression‐free survival (PFS) in the low‐score group was significantly longer than that in the high‐score group (median 7.8 vs. 3.5 months, p < 0.001). The median overall survival (OS) of the low‐score group was not reached at the time cutoff, with a 1‐year survival rate of 75.5%, whereas the median OS of the high‐score group was 8.5 months, showing a significant difference (p < 0.001). A high HCC‐GRIm score was a significant unfavorable factor associated with the PFS and OS in multivariate analyses (p = 0.002 and p < 0.001, respectively). Conclusions: The HCC‐GRIm score serves as a novel prognostic score for HCC patients treated with Atez/Bev. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
347. Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib.
- Author
-
Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, and Kakizaki, Satoru
- Subjects
- *
ATEZOLIZUMAB , *BEVACIZUMAB , *TERMINATION of treatment , *CHEMOEMBOLIZATION , *APPETITE loss , *PROTON magnetic resonance spectroscopy - Abstract
Background/Aim: A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC) in regard to progression‐free survival (PFS) overall survival (OS) has not been reported. We aimed to elucidate which of those given as initial treatment for u‐HCC has greater prognostic impact on PFS and OS of affected patients, retrospectively. Materials/Methods: From 2020 to January 2022, 251 u‐HCC (Child–Pugh A, ECOG PS 0/1, BCLC‐B/C) treated were enrolled (Atez/Bev‐group, n = 194; lenvatinib‐group, n = 57). PFS and OS were analyzed following adjustment based on inverse probability weighting (IPW). Results: There was a greater number of patients with macro‐vascular invasion in Atez/Bev‐group (22.7% vs. 8.8%, p = 0.022). In lenvatinib‐group, the frequencies of appetite loss (38.6% vs. 19.6%, p = 0.002), hypothyroidism (21.1% vs. 6.7%, p = 0.004), hand foot skin reaction (19.3% vs. 1.0%, p < 0.001), and diarrhea (10.5% vs. 4.6%, p = 0.012) were greater, while that of general fatigue was lower (22.8% vs. 26.3%, p = 0.008). Comparisons of therapeutic best response using modified response evaluation criteria in solid tumors (mRECIST) did not show significant differences between the present groups (Atez/Bev vs. lenvatinib: CR/PR/SD/PD = 6.1%/39.1%/39.1%/15.6% vs. 0%/48.0%/38.0%/14.0%, p = 0.285). In patients of discontinuation of treatments, 48.2% switched to lenvatinib, 10.6% continued beyond PD, 8.2% received another systemic treatment, 5.9% underwent transcatheter arterial chemoembolization (TACE), 3.5% received hepatic arterial infusion chemotherapy (HAIC), and 1.2% underwent surgical resection in Atez/Bev‐group, while 42.2% switched to Atez/Bev, 4.4% continued beyond PD, 4.4% received another systemic treatment, 2.2% nivolumab, 6.7% received TACE, and 2.2% received HAIC in lenvatinib‐group. Following adjustment with inverse probability weighting (IPW), Atez/Bev‐group showed better PFS (0.5−/1−/1.5‐years: 56.6%/31.6%/non‐estimable vs. 48.6%/20.4%/11.2%, p < 0.0001) and OS rates (0.5−/1−/1.5‐years: 89.6%/67.2%/58.1% vs. 77.8%/66.2%/52.7%, p = 0.002). Conclusion: The present study showed that u‐HCC patients who received Atez/Bev as a first‐line treatment may have a better prognosis than those who received lenvatinib. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
348. Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
- Author
-
Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, and Kakizaki, Satoru
- Subjects
- *
PROTEINS , *HYPERTENSION , *STATISTICS , *COMBINATION drug therapy , *CONFIDENCE intervals , *MULTIVARIATE analysis , *MONOCLONAL antibodies , *RETROSPECTIVE studies , *MANN Whitney U Test , *T-test (Statistics) , *BEVACIZUMAB , *DRUG side effects , *VASCULAR endothelial growth factors , *LOGISTIC regression analysis , *ODDS ratio , *HEPATOCELLULAR carcinoma , *CREATININE - Abstract
Introduction: Adverse events (AEs) of urinary protein from monoclonal antibodies against vascular endothelial growth factor are factors that often inhibit systemic therapy for unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate risk factors of urinary protein in the early period (<12 weeks) of atezolizumab plus bevacizumab treatment (Atez/Bev). Methods: From 2020 to June 2022, 193 uHCC patients treated with Atez/Bev at our affiliated hospitals were enrolled (median 73 years, 158 males, 183 Child-Pugh A, BCLC-0:A:B:C = 1:7:73:112). AEs related to urinary protein (≥G2) within 12 weeks were defined as significant, and related clinical features were analyzed retrospectively. Results: In analyses of risk factors of urinary protein-related AEs during the first 12 weeks after starting Atez/Bev using a logistic regression method, univariate analysis showed positive for hypertension (odds ratio [OR] 3.54, 95% CI: 1.28–9.80, p = 0.015) and baseline urinary protein and urine creatinine ratio (UPC: ≥0.16) (OR: 2.52, 95% CI: 1.09–5.83, p = 0.031) as pretreatment clinical factors, while elevation of urinary protein in the early period (baseline to 3 weeks) with delta UPC per 3 weeks (ΔUPC/3W) (≥0.23) (OR: 15.80, 95% CI: 6.15–40.50, p < 0.001) was a clinical factor after starting treatment. Multivariate analysis of only baseline clinical factors revealed positive for history of hypertension as the only predictive factor (OR: 3.20, 95% CI: 1.14–8.95, p = 0.027), while only ΔUPC/3W (≥0.23) (OR: 14.40, 95% CI: 4.91–42.00, p < 0.001) were noted in multivariate analysis including ΔUPC/3W. Predictive factors for ΔUPC/3W (≥0.23) were hypertension (OR: 3.50, 95% CI: 1.23–99.90, p = 0.019) and UPC (≥0.16) (OR: 6.12, 95% CI: 2.61–14.30, p < 0.001) in multiple analysis. Discussion/Conclusion: Urinary protein-related AEs are frequently observed during Atez/Bev treatment in uHCC patients with elevated ΔUPC/3W (≥0.23), and ΔUPC/3W (≥0.23) is often seen in patients with hypertension and/or UPC (≥0.16). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
349. Misunderstanding of hepatitis C virus (HCV) infection status by non–specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy.
- Author
-
Toyoda, Hidenori, Yasuda, Satoshi, Moriya, Akio, Itobayashi, Ei, Uojima, Haruki, Watanabe, Tsunamasa, Atsukawa, Masanori, Arai, Taeang, Ishikawa, Toru, Mikami, Shigeru, Hiraoka, Atsushi, Tsuji, Kunihiko, Oikawa, Tsunekazu, Tsubota, Akihito, Nozaki, Akito, Chuma, Makoto, Abe, Hiroshi, Shima, Toshihide, Kumada, Takashi, and Tanaka, Junko
- Subjects
- *
PHYSICIANS , *HEPATITIS C virus , *HEPATITIS C , *COMMUNICABLE diseases , *TREATMENT effectiveness - Abstract
With the increase in the number of patients with sustained virologic response (SVR) in whom hepatitis C virus (HCV) was eradicated by the anti-HCV therapy, there are now many individuals in whom serum HCV RNA is absent despite positive serum HCV antibodies. However, in general clinical practice, HCV infection remains usually screened by measurement of serum HCV antibodies and patients with SVR can be misunderstood regarding HCV infection status. In the multicenter study, we conducted interviews with administered questionnaires to SVR individuals who had regular hospital visits after SVR. The prevalence of experiencing an incorrect diagnosis of HCV infection after SVR was assessed. Individuals who experienced this misunderstanding were further asked where they experienced it and how it made them feel. In a survey of 2,246 SVR individuals, 197 individuals (8.8%) were misunderstood as having persistent HCV infection by medical doctors due to positive HCV antibody, despite the absence of HCV viremia. These misunderstandings occurred most prevalently at a private clinic (55.3%). More than half (53.3%) of these individuals felt anxious about their HCV infection with becoming unsure about their HCV eradication status. Misunderstanding HCV status is commonly occurred in SVR individuals. Specialists in hepatology and infectious diseases should broadly emphasize the fact that most patients with HCV antibodies are now HCV-free because of the use of anti-HCV therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
350. International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients.
- Author
-
Shiha, Gamal, Soliman, Reham, Mikhail, Nabiel N. H., Carrat, Fabrice, Azzi, Jessica, Nathalie, Ganne‐Carrié, Toyoda, Hidenori, Uojima, Haruki, Nozaki, Akito, Takaguchi, Koichi, Hiraoka, Atsushi, Atsukawa, Masanori, Abe, Hiroshi, Matsuura, Kentaro, Mikami, Shigeru, Watanabe, Tsunamasa, Tsuji, Kunihiko, Ishikawa, Toru, Suri, Vithika, and Osinusi, Anu
- Subjects
- *
CHRONIC hepatitis C , *DISEASE risk factors , *HEPATITIS C virus , *LOG-rank test , *ANTIVIRAL agents , *ANIMAL health surveillance - Abstract
We have recently demonstrated the ability of a simple predictive model (GES) score to determine the risk of hepatocellular carcinoma (HCC) after using direct‐acting antivirals. However, our results were restricted to Egyptian patients with hepatitis C virus (HCV) genotype 4. Therefore, we studied a large, independent cohort of multiethnic populations through our international collaborative activity. Depending on their GES scores, patients are stratified into low risk (≤ 6/12.5), intermediate risk (> 6–7.5/12.5), and high risk (> 7.5/12.5) for HCC. A total of 12,038 patients with chronic HCV were analyzed in this study, of whom 11,202 were recruited from 54 centers in France, Japan, India, the U.S., and Spain, and the remaining 836 were selected from the Gilead‐sponsored randomized controlled trial conducted across the U.S., Europe, Canada, and Australia. Descriptive statistics and log‐rank tests. The performance of the GES score was evaluated using Harrell's C‐index (HCI). The GES score proved successful at stratifying all patients into 3 risk groups, namely low‐risk, intermediate‐risk, and high‐risk. It also displayed significant predictive value for HCC development in all participants (p <.0001), with HCI ranging from 0.55 to 0.76 among all cohorts after adjusting for HCV genotypes and patient ethnicities. The GES score can be used to stratify HCV patients into 3 categories of risk for HCC, namely low‐risk, intermediate‐risk, and high‐risk, irrespective of their ethnicities or HCV genotypes. This international multicenter validation may allow the use of GES score in individualized HCC risk‐based surveillance programs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.